Evidence map›Paper›PMID 42889944›Full record

ReviewFrontiers in pharmacology2026

Natural products targeting mitochondrial homeostasis: a four-dimensional framework integrating dynamics, mitophagy, pharmacokinetics, and translational safety.

Zhi-Yun Xiang, Xiu-Hua Yang, Wen-Ying Lan, Xin-Yu Xiao, Qun Huang, Lin-Lin Yang

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhi-Yun Xiang *Chengdu Xinjin District Hospital of Traditional Chinese Medicine, Chengdu, China.
Xiu-Hua Yang *Department of General Surgery, Deyang Sixth People's Hospital, Deyang, China.
Wen-Ying Lan *Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Xin-Yu XiaoChengdu University of Traditional Chinese Medicine, Chengdu, China.
Qun HuangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Lin-Lin YangAffiliated Meishan Hospital of Chengdu University of Traditional Chinese Medicine / Traditional Chinese Medicine Hospital of Meishan, Meishan, Sichuan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dysregulated mitochondrial dynamics, including fission, fusion, biogenesis, and mitophagy, underlie the pathogenesis of many diseases. Natural products have the potential for multi-target therapy, but insufficient understanding of their mechanisms of action and pharmacokinetic limitations hinder their clinical translation. Objective: This review proposes a regulatory framework covering the four dimensions of biogenesis, morphology, quality control, and defense, aiming to systematically clarify how natural products regulate mitochondrial function and critically evaluate their translational potential. The framework emphasizes that inter-organelle contact platforms, such as mitochondria-endoplasmic reticulum contact sites (MERCs) and mitochondrial-lysosomal contact sites (MLCs), are key sites through which natural products exert regulatory effects. Methods: Major scientific databases, including PubMed, Web of Science, and Scopus, were searched, and evidence on mechanisms, pharmacokinetics, and toxicology from preclinical and clinical studies was comprehensively reviewed. Results: Natural products can selectively regulate key mitochondrial pathways and regulatory nodes, including the AMPK/SIRT1/PGC-1α axis involved in mitochondrial biogenesis, the DRP1 axis involved in mitochondrial fission, and the PINK1/Parkin pathway involved in mitophagy. Representative metabolites include resveratrol, curcumin, and Conclusion: Natural products are powerful multidimensional regulators of mitochondrial homeostasis. In order to fully realize their therapeutic potential, strategies must be adopted to overcome PK/PD mismatch, including the development of targeted delivery systems, in-depth analysis of microbiome-metabolite interactions, and the integration of artificial intelligence and CRISPR-based technological innovation to support precision therapy.

Indexed as

gut microbiota–mitochondria axismitochondrial dynamicsmitohormesismitophagynatural productspharmacokinetics

Identifiers

PMID42889944
PMCPMC13670514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.